Brookstone Capital Management Has $35.35 Million Stock Holdings in Eli Lilly and Company $LLY

Brookstone Capital Management grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 10.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 46,325 shares of the company’s stock after purchasing an additional 4,558 shares during the period. Brookstone Capital Management’s holdings in Eli Lilly and Company were worth $35,346,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Symmetry Partners LLC boosted its holdings in shares of Eli Lilly and Company by 19.6% in the third quarter. Symmetry Partners LLC now owns 2,319 shares of the company’s stock worth $1,769,000 after acquiring an additional 380 shares during the period. Cape ANN Savings Bank purchased a new stake in Eli Lilly and Company in the third quarter worth about $440,000. Value Partners Investments Inc. lifted its stake in shares of Eli Lilly and Company by 0.5% in the third quarter. Value Partners Investments Inc. now owns 3,239 shares of the company’s stock worth $2,470,000 after buying an additional 15 shares in the last quarter. James Hambro & Partners LLP raised its stake in Eli Lilly and Company by 4.6% during the 3rd quarter. James Hambro & Partners LLP now owns 343 shares of the company’s stock valued at $262,000 after buying an additional 15 shares during the last quarter. Finally, Manchester Financial Inc. raised its holdings in Eli Lilly and Company by 25.0% in the 3rd quarter. Manchester Financial Inc. now owns 1,878 shares of the company’s stock worth $1,433,000 after purchasing an additional 375 shares during the period. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Sanford C. Bernstein reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Friday, December 19th. Weiss Ratings reissued a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a report on Monday, December 1st. Finally, Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 1st. Four research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,155.36.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $1,077.06 on Friday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99. The stock has a market capitalization of $1.02 trillion, a P/E ratio of 52.69, a P/E/G ratio of 1.09 and a beta of 0.37. The firm’s 50 day moving average is $981.27 and its 200-day moving average is $839.03.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the prior year, the firm posted $1.18 EPS. The business’s revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. The ex-dividend date is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is 29.35%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.